Israel-based Embryonics collaborates with Jaslok-FertilTree International Fertility Centre – ET HealthWorld

Embryonics has trained its algorithms using tens of thousands of data points from large clinics in the US, Israel, Europe, and Asia and the first product to reach the market is UBAR, CE marked assistive embryo selection tool. Designed to aid embryologists in selecting which embryo(s) to transfer is a huge success. It addresses one of the most crucial steps for IVF success. UBAR’s purpose is to assist embryologists in a highly subjective decision-making step, utilising a more objective data driven approach, and is not intended to replace the human factor. UBAR, builds on technology using bleeding edge deep learning in the clinical setting. Trained using a large, multi-centre dataset, UBAR is a cloud-based software which uses time-lapse videos or single images of blastocysts to predict implantation probability, automatically annotate morphokinetic events and assist embryo selection using a data-driven approach.

Dr Parikh’s said, “There are characteristics differentiating a good blastocyst stage embryo which has a possibility of implanting from one that has less potential. Algorithms created by AI and deep machine learning detect signals from developing embryos most likely to result in babies. These include healthy and equal division of embryonic cells. Signals pick up the quality and placement of the inner cell mass which ultimately becomes the baby. The trophectoderm cells surrounding the inner cell mass form the placenta. The timing of the expansion of the blastocyst at a particular time point also contributes to its success”.

“When we compute these characteristics, the software comes up with a score from 1-5, five being the best. We have conducted interim analysis and have computed a predictive score most likely to result in a pregnancy. This method is simple and inexpensive.” she added.

Talking about the new partnership, Tal Landman, CEO, Embryonics said, “We at Embryonics are delighted to finally have our presence in India through Jaslok Hospital and UBAR. UBAR’s purpose is to assist embryologists in a highly subjective decision-making step, utilising a more objective data driven approach, and is not intended to replace the human factor. I am thankful to Dr Parikh, who has chosen our product in making her dream of bringing happiness to so many Indian couples struggling with infertility. 2022 is also a special year for India and Israel as we celebrate 30 years of diplomatic relations, and I am elated that Embryonics could also enter the Indian market in the same year.”

Karan Kalra, General Manager, APAC & MEA, said, “Partnering with a prestigious clinic as Jaslok-FertilTree International is a great honour and we are looking forward to helping prospective parents fulfilling their dreams using the latest technology. The Jaslok-FertilTree collaboration with Embryonics is taking the frontiers of IVF towards a new era of AI-driven personalised medicine.”